Companies › Guangzhou Novaken Pharm
2 active drug programs in 80 registered trials: 33 Phase 4, 19 Phase 3, 16 Phase 2, 12 Phase 1; Neurology, Cardiovascular, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dexmedetomidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 2 | Preoperative Sedation; Emergence Delirium; Laceration of Skin; Vaginal Delivery … | – |
| XJN010 Nasal Spray unclear mechanism | – | Phase 2 | Parkinson Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06712186 | Dexmedetomidine | Phase 1 | Elective Surgical Patient | Cardiovascular | Nov 2024 |
| NCT06761092 | Dexmedetomidine | Phase 4 | Emergence Delirium | Psychiatry | Feb 2025 |
| NCT05849597 | Dexmedetomidine | Phase 3 | Intensive Care Unit Delirium | Psychiatry | Feb 2025 |
| NCT06702488 | Dexmedetomidine | Phase 1 | Mental Disorder | Other | Apr 2025 |
| NCT06702488 | Dexmedetomidine | Phase 1 | Mental Disorder | Other | Apr 2025 |
| NCT05934669 | Dexmedetomidine | Phase 4 | Laceration of Skin | Psychiatry | May 2025 |
| NCT06970626 | Dexmedetomidine | Phase 2 | Laparoscopic Sleeve Gastrectomy | Other | Jun 2025 |
| NCT06970678 | Dexmedetomidine | Phase 1 | Laparoscopic Sleeve Gastrectomy (LSG) | Other | Jun 2025 |
| NCT06823349 | Dexmedetomidine | Phase 4 | Vaginal Delivery | Other | Jun 2025 |
| NCT07078201 | Dexmedetomidine | Phase 4 | Spinal Anesthesia Duration | Other | Jul 2025 |
| NCT06252662 | Dexmedetomidine | Phase 4 | Breast Cancer | Oncology | Jul 2025 |
| NCT06740903 | Dexmedetomidine | Phase 2 | Hemodynamics Instability | Gastroenterology | Aug 2025 |
| NCT07022821 | Dexmedetomidine | Phase 4 | Postoperative Pain | Other | Aug 2025 |
| NCT07034300 | Dexmedetomidine | Phase 4 | Post-operative Pain | Other | Aug 2025 |
| NCT07024043 | Dexmedetomidine | Phase 1 | Efficacy of Drugs in Pain Management | Other | Sep 2025 |
| NCT06778811 | Dexmedetomidine | Phase 4 | Sleep Wake Disorders | Neurology | Sep 2025 |
| NCT05821972 | Dexmedetomidine | Phase 4 | Sedation | Psychiatry | Oct 2025 |
| NCT06853431 | Dexmedetomidine | Phase 4 | Preoperative Anxiety | Psychiatry | Nov 2025 |
| NCT06087510 | Dexmedetomidine | Phase 4 | Scoliosis Correction | Genitourinary | Dec 2025 |
| NCT05031026 | Dexmedetomidine | Phase 4 | Liver Transplant; Complications | Other | Dec 2025 |
| NCT06067958 | Dexmedetomidine | Phase 3 | Retinopathy of Prematurity | Ophthalmology | Dec 2025 |
| NCT03384563 | Dexmedetomidine | Phase 4 | Pediatric Anesthesia | Other | Dec 2025 |
| NCT06978192 | Dexmedetomidine | Phase 2 | Herpes Zoster (HZ) | Infectious disease | Feb 2026 |
| NCT07350928 | Dexmedetomidine | Phase 3 | Breast Cancer | Oncology | Mar 2026 |
| NCT07434206 | Dexmedetomidine | Phase 2 | Thyroid Neoplasms | Oncology | Mar 2026 |
| NCT07168720 | Dexmedetomidine | Phase 2 | Preoperative Sedation | Other | Mar 2026 |
| NCT07156773 | XJN010 Nasal Spray | Phase 2 | Parkinson Disease | Neurology | Mar 2026 |
| NCT07080229 | Dexmedetomidine | Phase 3 | Cataract | Cardiovascular | Apr 2026 |
| NCT04801589 | Dexmedetomidine | Phase 3 | Delirium | Psychiatry | Apr 2026 |
| NCT05640453 | Dexmedetomidine | Phase 4 | Pregabalin | Cardiovascular | May 2026 |
| NCT06979141 | Dexmedetomidine | Phase 3 | Cough | Other | Jun 2026 |
| NCT06490731 | Dexmedetomidine | Phase 1 | Haemodynamic Rebound | Other | Jun 2026 |
| NCT07590752 | Dexmedetomidine | Phase 2 | Pain, Postoperative | Psychiatry | Jun 2026 |
| NCT07611890 | Dexmedetomidine | Phase 4 | Laryngoscopic Stress Response | Other | Aug 2026 |
| NCT06274333 | Dexmedetomidine | Phase 3 | Percutaneous Nephrolithotripsy (PCNL) | Other | Aug 2026 |
| NCT07513935 | Dexmedetomidine | Phase 4 | Intraoperative Awareness | Other | Sep 2026 |
| NCT06943404 | Dexmedetomidine | Phase 2 | Acute Stress Reaction | Psychiatry | Sep 2026 |
| NCT03089905 | Dexmedetomidine | Phase 3 | Anesthesia | Other | Oct 2026 |
| NCT06958367 | Dexmedetomidine | Phase 1 | Aki After Ascending Aortic Surgeries | Cardiovascular | Nov 2026 |
| NCT06859892 | Dexmedetomidine | Phase 4 | Adults | Cardiovascular | Nov 2026 |
| NCT07519863 | Dexmedetomidine | Phase 2 | Emergence Delirium in Pediatric Anesthesia | Other | Nov 2026 |
| NCT07799311 | Dexmedetomidine | Phase 4 | Emergence Delirium, Anesthesia | Psychiatry | Nov 2026 |
| NCT07462195 | Dexmedetomidine | Phase 4 | Thyroid Diseases | Metabolic and endocrine | Nov 2026 |
| NCT07167316 | Dexmedetomidine | Phase 1 | The Role of the LC-NA System in Sleep Regulation | Other | Dec 2026 |
| NCT07427446 | Dexmedetomidine | Phase 4 | Emergence Delirium | Psychiatry | Dec 2026 |
| NCT04916197 | Dexmedetomidine | Phase 4 | Acute Ischemic Stroke | Neurology | Dec 2026 |
| NCT05577962 | Dexmedetomidine | Phase 4 | Opioid-free Anesthesia | Other | Dec 2026 |
| NCT07878156 | Dexmedetomidine | Phase 3 | Posterior Fossa Tumor | Oncology | Dec 2026 |
| NCT07767383 | Dexmedetomidine | Phase 4 | Knee Arthroscopic Surgery | Other | Dec 2026 |
| NCT07184801 | Dexmedetomidine | Phase 3 | Medical Thoracoscopy | Other | Dec 2026 |
| NCT05383495 | Dexmedetomidine | Phase 3 | Laceration of Skin | Other | Dec 2026 |
| NCT07550881 | Dexmedetomidine | Phase 2 | Acute Anxiety States | Psychiatry | Dec 2026 |
| NCT05303987 | Dexmedetomidine | Phase 2 | Obstructive Sleep Apnea | Respiratory | Jan 2027 |
| NCT07389096 | Dexmedetomidine | Phase 4 | Opioid Free Anesthesia | Other | Jan 2027 |
| NCT07824817 | Dexmedetomidine | Phase 4 | Hemodynamic Response | Other | Feb 2027 |
| NCT07669012 | Dexmedetomidine | Phase 1 | Sedation and Analgesia | Other | Feb 2027 |
| NCT06335407 | Dexmedetomidine | Phase 1 | Alcohol Use Disorder (AUD) | Psychiatry | Feb 2027 |
| NCT05712707 | Dexmedetomidine | Phase 1 | Opioid Use Disorder | Psychiatry | Feb 2027 |
| NCT07308756 | Dexmedetomidine | Phase 4 | General Anesthesia | Genitourinary | Mar 2027 |
| NCT07392177 | Dexmedetomidine | Phase 2 | Insomnia | Psychiatry | Mar 2027 |
The 60 nearest readouts of 80 trials; the rest in the app.
BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas
Teikoku Pharma USA Santen SAS Ascension Health Exciva Oticara Australia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.